Safety and Tolerability of Modafinil for Methamphetamine Dependence

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This 7 week, open-label pilot clinical trial will examine the safety and tolerability of modafinil up to 400mg/day as a potential treatment to reduce methamphetamine use in methamphetamine-dependent volunteers.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Arkansas
• Collaborator: National Institute on Drug Abuse (NIDA)
• Treatments: Armodafinil; Methamphetamine; Modafinil

Criteria

Inclusion Criteria:

• 18-65 years old

• not currently enrolled in a treatment program

• subjects must have a history of methamphetamine use with recent use confirmed by a positive urine toxicology screen for amphetamines during the month prior to study entry

• subjects must meet DSM-IV criteria for amphetamine dependence as assessed by the substance abuse section of the Structured Clinical Interview for DSM-IV (SCID)

• women of childbearing age must have a negative pregnancy test to enroll in this study, agree to monthly pregnancy testing, and agree to use appropriate forms of birth control for the duration of the study

Exclusion Criteria:

• current diagnosis of alcohol, opiate, or sedative physical dependence

• ill health (e.g., major cardiovascular, renal, endocrine, hepatic disorder)

• history of schizophrenia, or bipolar type I disorder

• present or recent use of over-the-counter or prescription psychoactive drug or drug(s) that would be expected to have major interaction with drug to be tested

• medical contraindication to receiving study medications (e.g., allergy to modafinil, treatment with cyclosporine, clomipramine, or desipramine)

• Current suicidality or psychosis

• liver function tests (i.e., liver enzymes) greater than three times normal levels

• pregnancy or breastfeeding